INTRODUCTION Crohn's disease (CD) involves the entire gastrointestinal tract, including the mouth. Numerous cytokines play a role in the regulation of inflammatory process in CD. OBJECTIVES The aim of the study was to examine the prevalence of oral lesions in adult patients with CD and to investigate whether salivary concentrations of interleukin 1 beta (IL-1 beta), interleukin 6 (IL-6), and tumor necrosis factor alpha (TNF-alpha) are associated with the activity and oral manifestations of CD. PATIENTS AND METHODS A prospective study included 95 adult patients: 52 with active CD and 43 with inactive CD. The control group involved 45 subjects without CD. We performed blood tests, careful oral examination, and measurement of IL-1 beta, IL-6, and TNF-alpha in unstimulated whole saliva by enzyme-linked immunosorbent assays. RESULTS IL-1 beta, IL-6, and TNF-alpha were significantly elevated in patients with active CD. IL-1 beta levels were 289.8 +/- 52.7 in patients with active CD vs. 196.7 +/- 42.9 pg/ml in patients with inactive CD (P < 0.039), and 196.7 +/- 42.9 pg/ml (P < 0.01) in controls. IL-6 levels were 13.8 +/- 4.2 vs. 7.2 +/- 3.1 pg/ml (P < 0.041), respectively, and 6.3 +/- 1.4 pg/ml (P < 0.001) in controls. TNF-alpha levels were 32.5 +/- 8.7 vs. 10.2 +/- 6.3 pg/ml (P < 0.002), respectively, and 6.8 +/- 2.8 pg/ml (P < 0.001) in controls. We observed CD-specific oral lesions: diffuse asymptomatic buccal swelling in 12 patients (23%) and cobblestoning in 5 patients (11.3%). CD-nonspecific lesions were observed in 17 patients (32.7%) with active CD, in 11 patients (25.6%) with inactive CD, and in 6 controls (13.3%). In active CD, higher salivary IL-6 and TNF-alpha and serum C-reactive protein levels correlated with specific oral lesions. CONCLUSIONS In patients with active CD, salivary IL-1 beta, IL-6, and TNF-alpha levels are higher than in patients with inactive disease and controls. Elevated salivary IL-6 and TNF-alpha levels correlate with specific oral lesions. These cytokines may be used as markers of active CD, but the finding should be confirmed in a larger group of patients.